YAP1 and cancer: There are several clinical trials underway using verteporfin, as it is FDA-approved in combination with light to treat eye diseases; only one of these current trials is for cancer therapy focusing on EGFR-mutated glioblastoma, and it remains unclear whether verteporfin’s effects are mediated through disruption of the YAP/TAZ and TEAD interaction.